ArticleProceedings of the National Academy of Sciences of the United States of America2016
Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Recent advances in the pharmacology of voltage-gated ion channels.Pharmacological reviews · 2025Review
- Rational design of humanized antibody inhibitors for cathepsin S.Archives of biochemistry and biophysics · 2024Article
- Protection from acute lung injury by a peptide designed to inhibit the voltage-gated proton channel.iScience · 2023Article
- Kv1.3 inhibition attenuates neuroinflammation through disruption of microglial calcium signaling.Channels (Austin, Tex.) · 2021Review
- The Kv1.3 KBiologia futura · 2021Review
- Therapeutic Antibodies Targeting Potassium Ion Channels.Handbook of experimental pharmacology · 2021Article
- A humanized antibody inhibitor for cathepsin L.Protein science : a publication of the Protein Society · 2020Article
- Rational Design of a Humanized Antibody Inhibitor of Cathepsin B.Biochemistry · 2020Article
- Epitope-directed antibody selection by site-specific photocrosslinking.Science advances · 2020Article
- Antibodies Targeting KBioelectricity · 2019Article
- Antibodies and venom peptides: new modalities for ion channels.Nature reviews. Drug discovery · 2019Review
- A Switchable Site-Specific Antibody Conjugate.ACS chemical biology · 2018Article
- The impact of structural biology in medicine illustrated with four case studies.Journal of molecular medicine (Berlin, Germany) · 2018Review
- Animal protein toxins: origins and therapeutic applications.Biophysics reports · 2018Article
- Eplerenone Reverses Cardiac Fibrosis via the Suppression of Tregs by Inhibition of Kv1.3 Channel.Frontiers in physiology · 2018Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
A variable region fusion strategy was used to generate an immunosuppressive antibody based on a novel "stalk-knob" structural motif in the ultralong complementary-determining region (CDR) of a bovine antibody. The potent Kv1.3 channel inhibitory peptides Moka1-toxin and Vm24-toxin were grafted into different CDRs of the humanized antibodies BVK and Synagis (Syn) using both β-sheet and coiled-coil linkers. Structure-activity relationship efforts led to generation of the fusion protein Syn-Vm24-CDR3L, which demonstrated excellent selectivity and potency against effector human memory T cells (subnanomolar to picomolar EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.